Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Russian Direct Investment Fund","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Combination Between AstraZeneca and The First Component of Sputnik V Vaccine (Sputnik Light) Demonstrates High Immunogenicity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Russian Direct Investment Fund"}]

Russian Direct Investment Fund

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

A Combination Between AstraZeneca and The First Component of Sputnik V Vaccine (Sputnik Light) Demonstrates High Immunogenicity

Details:

The Sputnik Light vaccine is based on a well-studied human adenoviral vector platform that has proven to be safe and effective, with no long-term side effects, as confirmed in over 250 clinical trials conducted globally over the past two decades .

Lead Product(s): ChAdOx1 nCoV-19,Gam-COVID-Vac

Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: AstraZeneca

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 20, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY